Overview

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Status:
Completed

Trial end date:
2016-12-06

Target enrollment:

Participant gender:

Summary

This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy. The objectives of the trial are to compare the efficacy and safety of afatinib versus methotrexate

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Afatinib
Methotrexate